BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35846420)

  • 1. Thyroglobulin-Based Risk Factor Repositioning for Determining Radioactive Iodine Activity in Patients with Papillary Thyroid Carcinoma: a Multicenter Retrospective Cohort Study.
    Jeon S; Kwon SY; Lee SW; Bae SK
    Nucl Med Mol Imaging; 2022 Aug; 56(4):173-180. PubMed ID: 35846420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 4. Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.
    Jeong GC; Song M; Park HJ; Min JJ; Bom HS; Cho SG; Park KS; Kang SR; Kim J; Song HC; Kwon SY
    Nucl Med Mol Imaging; 2016 Dec; 50(4):329-336. PubMed ID: 27994688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer.
    Mao Y; Lin R; Wang Y; Yu J
    Quant Imaging Med Surg; 2024 May; 14(5):3665-3675. PubMed ID: 38720856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
    Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
    Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
    Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer.
    Kim H; Kim SJ; Kim IJ; Kim K; Kim S; Kim BH; Kim SS; Kyung JY
    Nucl Med Mol Imaging; 2013 Dec; 47(4):268-72. PubMed ID: 24900123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy.
    Kim KH; Kim MH; Lim YJ; Lee IS; Bae JS; Lim DJ; Baek KH; Lee JM; Kang MI; Cha BY
    Int J Endocrinol; 2015; 2015():318916. PubMed ID: 25649811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
    Pan M; Li Z; Jia M; Lu X
    Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
    Ramos da Silva F; Rosario PW; Mourão GF
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study.
    Kwon SY; Lee SW; Kong EJ; Kim K; Kim BI; Kim J; Kim H; Park SH; Park J; Park HL; Oh SW; Won KS; Ryu YH; Yoon JK; Lee SJ; Lee JJ; Chong A; Jeong YJ; Jeong JH; Cho YS; Cho A; Cheon GJ; Choi EK; Hwang JP; Bae SK;
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):561-571. PubMed ID: 31820047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined role of lymph node ratio and serum thyroglobulin levels in predicting prognosis of papillary thyroid carcinoma.
    Jeon S; Kwon SY; Ryu YJ; Kang SR; Yoo SW; Cho SG; Kim J; Song HC; Sohn SJ; Bom HS; Min JJ
    Nucl Med Commun; 2020 Aug; 41(8):733-739. PubMed ID: 32427697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
    Rosario PW; Mourão GF
    Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
    Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
    Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer.
    Neshandar Asli I; Siahkali AS; Shafie B; Javadi H; Assadi M
    Mol Imaging Radionucl Ther; 2014 Jun; 23(2):54-9. PubMed ID: 24963446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer.
    Song M; Jeon S; Kang SR; Jabin Z; Yoo SW; Min JJ; Bom HS; Cho SG; Kim J; Song HC; Kwon SY
    Nucl Med Mol Imaging; 2018 Aug; 52(4):287-292. PubMed ID: 30100941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.